Atomic AI closes $35M Series A financing
Biotech firm Atomic AI recently announced it the closing of a $35 million Series A round led by Playground Global, with participation from 8VC, Factory HQ, Greylock, NotBoring, AME Cloud Ventures, GitHub’s ex-CEO Nat Friedman, Doug Mohr, Curai CEO Neal Khosla, and UC Berkeley Professor and Arc Institute co-founder Patrick Hsu. Read More
Mixing cancer drugs in nanoparticle combinations improves efficacy in mice
Using polymer nanoparticles to carry multiple cancer drugs achieves better outcomes than administering the combination of therapeutics without a delivery vehicle, according to preclinical research published on 26 January in Nature Nanotechnology. Read More
'Living medicine' for drug-resistant lung infections
Researchers have engineered a bacterium that serves as a “living medicine” to treat antibiotic-resistant lung infections -- the leading cause of hospital mortality. The research, published January 19 in the journal Nature Biotechnology and supported through CaixaResearch Health, focused on the antibiotic-resistant bacterium Pseudomonas aeruginosa, a common source of difficult-to-treat hospital infections. Read More
Machine learning models predict release profile to accelerate drug development
Machine learning models have predicted the drug release profiles of long-acting injectable medicines, suggesting that the algorithms can accelerate the development of a promising class of therapies. Read More
Wyss Institute launches RNA therapeutics startup EnPlusOne Biosciences
Wyss Institute at Harvard University has partnered with Northpond Labs to launch EnPlusOne Biosciences. The startup aims to bring versatile, scalable RNA synthesis technology to market, with the goal of unlocking the development of new RNA drugs, vaccines, and gene-editing therapies. Read More
Functional genomics reveals gateway to intracellular targets for large molecules
Complementary genome-scale, chemical-genetic approaches have revealed a cellular gateway that could allow large molecules to enter cells, providing new opportunities to develop drugs for intracellular targets, according to University of California San Francisco (UCSF) researchers. Read More
New research shows smallpox vaccine trains T cells to recognize mpox
Scientists from the La Jolla Institute for Immunology have found new evidence that the vaccinia vaccine MVA-BN (brand name JYNNEOS) can train virus-fighting T cells to recognize the monkeypox (mpox) virus. Read More
Conferences
Science Briefs
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Connect
